Log in

NASDAQ:NVCR - Novocure Stock Price, Forecast & News

$70.04
+4.54 (+6.93 %)
(As of 03/31/2020 06:24 AM ET)
Today's Range
$64.57
Now: $70.04
$70.50
50-Day Range
$57.05
MA: $75.61
$95.75
52-Week Range
$41.51
Now: $70.04
$98.84
Volume1.01 million shs
Average Volume1.29 million shs
Market Capitalization$6.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.27
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More
Novocure logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share

Profitability

Net Income$-7,230,000.00

Miscellaneous

EmployeesN/A
Market Cap$6.98 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Novocure (NASDAQ:NVCR) Frequently Asked Questions

How has Novocure's stock been impacted by COVID-19 (Coronavirus)?

Novocure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has increased by 3.9% and is now trading at $70.04. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novocure.

When is Novocure's next earnings date?

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Novocure.

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, February, 27th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.02 by $0.02. The medical equipment provider earned $99.23 million during the quarter, compared to analysts' expectations of $99.10 million. Novocure had a negative net margin of 2.06% and a negative return on equity of 4.17%. The company's quarterly revenue was up 42.4% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. View Novocure's earnings history.

What guidance has Novocure issued on next quarter's earnings?

Novocure issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

What price target have analysts set for NVCR?

6 brokerages have issued 12 month target prices for Novocure's shares. Their forecasts range from $79.00 to $97.00. On average, they anticipate Novocure's stock price to reach $87.40 in the next year. This suggests a possible upside of 24.8% from the stock's current price. View analysts' price targets for Novocure.

Has Novocure been receiving favorable news coverage?

Headlines about NVCR stock have trended very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novocure earned a coverage optimism score of -3.7 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutNovocure.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the following people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $70.04.

How big of a company is Novocure?

Novocure has a market capitalization of $6.98 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.  View additional information about Novocure.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com/.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  411 (Vote Outperform)
Underperform Votes:  386 (Vote Underperform)
Total Votes:  797
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel